http://www.wsj.com/articles/teva-offers-to-buy-mylan-for-82-a-share-1429620984The part we care about. Not that I truly understand the implication of Teva developing a generic or the merger of pharmaceuticals in general.
For Teva and Mylan in recent years, sales of brand-name products have helped cushion the blows. Teva’s revenue and profit have been boosted by a brand-name multiple-sclerosis drug called Copaxone, while Mylan has benefited from the branded EpiPen emergency treatment for allergic reactions.
But each company is facing competition for the key moneymakers. Just last week, Novartis AG and partner Momenta Pharmaceuticals Inc. won U.S. regulatory approval to sell a generic version of Teva’s Copaxone. Meantime, Teva is among the companies trying to develop a generic EpiPen.
Topic: Mylan takeover/merger by Teva (Read 1070 times)
